Opendata, web and dolomites

MetaTox-HS

Advanced Solutions for High Sensitivity Metabolism and Toxicity Assays

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MetaTox-HS project word cloud

Explore the words cloud of the MetaTox-HS project. It provides you a very rough idea of what is the project "MetaTox-HS" about.

engineering    party    trade    320m    position       global    stages    requirement    academia    revenue    kits    14    polymer    instrumentation    5m    luxcel    pilot    solution    businesses    industry    laboratory    innovative    turnover    boost    commercial    serious    components    tests    proof    contract    either    vitro    vivo    manufacturing    oct    cum    sub    verification    made    market    doxycheck    fluorescence    highlights    enormous    scoring    opportunity    bedside    drug    metatox    platform    prototyped    previously    toxicity    consumable    accessible    secures    flexible    demonstrated    submitted    translate    critical    mitoxpress    13    plate    final    electronic    jobs    3rd    sole    uhs    disease    synergy    biosciences    passing    few    expensive    labs    review    creation    reader    16    challenger    scientific    performance    readiness    hs    innovation    dominated    est    beneficiary    cell    metabolism    standard    models    microfabrication    full    pharmaceutical    capex    job    completes    ambition    ltd    scientists    bench    write    2023    re    criteria    consolidating    clear    reg    plan    lux    nanosensor    3bn    instruments    business   

Project "MetaTox-HS" data sheet

The following table provides information about the project.

Coordinator
LUXCEL BIOSCIENCES LTD 

Organization address
address: BIOTRANSFER UNIT SUITE 3-32 BIOL
city: Cork
postcode: T12
website: www.luxcel.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website http://www.agilent.com/en/metatox-hs
 Total cost 1˙469˙333 €
 EC max contribution 1˙028˙533 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LUXCEL BIOSCIENCES LTD IE (Cork) coordinator 1˙028˙533.00

Map

 Project objective

'Drug failure and high development cost (est. €2.3bn/new drug) has driven enormous growth in market need for scientific tests and models of disease, for researchers in academia, institutions and the pharmaceutical industry, that better translate from the bench (in vitro) to the bedside (in vivo). Critical tests are either not available, or only available on a few large, expensive dedicated instruments.

Luxcel Biosciences Ltd (LUX) has prototyped innovation that can now bring these high performance tests, to all laboratory scientists, for use on standard laboratory instrumentation already available in est. 20,000 labs (fluorescence plate reader), without requirement for CapEx.

LUX’s business innovation solution is a platform of low cost, flexible, easy to use and accessible in vitro cell metabolism and toxicity test kits and consumable products (MitoXpress UHS® and dOxycheck™) made possible through innovative synergy of LUX’s fluorescence nanosensor technology, together with advanced polymer microfabrication and electronic engineering.

MetaTox-HS project, completes the final stages of development, verification, pilot process and manufacturing readiness, together with dissemination and exploitation activities, to bring the full product solution to market and secures EU based revenue and job creation; 13 new jobs and €14.5m cum turnover by 2023, consolidating LUXCEL’s EU position (2 YR), and ambition to become a serious #2 challenger in this est. €320m accessible US and global market (5 YR), currently dominated by US businesses.

Proposal previously submitted Oct ’16, scoring highly, passing all three criteria. Following a full commercial review LUXCEL has taken a sole beneficiary role, with key enabling technology provided through 3rd party sub-contract. A full re-write highlights: clear product components, demonstrated proof-of-concept, well-defined market opportunity and strong commercial plan to boost growth. '

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "METATOX-HS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "METATOX-HS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

SHN (2017)

Universal Smart Hypodermic Needle for preventing reuse and accidental pricks

Read More  

SUPPLEPRINT (2018)

Super Productive Line Printing Inkjet

Read More  

Gri3D (2018)

The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.

Read More